Complement activation in myasthenia gravis plasma by Torpedo acetylcholine receptor liposomes
- PMID: 4077155
- DOI: 10.3109/08820138509047609
Complement activation in myasthenia gravis plasma by Torpedo acetylcholine receptor liposomes
Abstract
The purpose of this study was to determine if antibodies from patients with myasthenia gravis (MG) react in a biologically relevant manner with membrane bound Torpedo californica acetylcholine receptor (AChR). Antibody-mediated complement activation was measured in plasma from 15 patients with MG and 9 controls following incubation with Torpedo AChR-rich membrane vesicles (AChR liposomes). Significantly more (p less than 0.001) complement activation occurred in the patient samples compared with the controls. Torpedo AChR liposomes are well characterized and have been widely used to study the structure and function of AChR. These results suggest that Torpedo AChR liposomes may also be used in immunologic studies with autoantibodies from patients with MG.
Similar articles
-
Anti-acetylcholine receptor antibodies in myasthenia gravis: binding to membrane-bound Torpedo AChR.Ann N Y Acad Sci. 1987;505:557-65. doi: 10.1111/j.1749-6632.1987.tb51323.x. Ann N Y Acad Sci. 1987. PMID: 3479936 No abstract available.
-
Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG).Clin Exp Immunol. 1997 Sep;109(3):538-46. doi: 10.1046/j.1365-2249.1997.4701367.x. Clin Exp Immunol. 1997. PMID: 9328134 Free PMC article.
-
T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.Autoimmunity. 1998;27(2):79-90. doi: 10.3109/08916939809008038. Autoimmunity. 1998. PMID: 9583739
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
-
Adsorption column for myasthenia gravis treatment: Medisorba MG-50.Ther Apher Dial. 2003 Feb;7(1):78-84. doi: 10.1046/j.1526-0968.2003.00008.x. Ther Apher Dial. 2003. PMID: 12921120 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
